Bioventus (BVS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is BVS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Bioventus Inc. ( BVS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton…

Bioventus (BVS) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.15 per share a year ago.…

Bioventus NASDAQ: BVS reported third-quarter revenue growth of 3% as strength in its Pain Treatments business, Ultrasonics operation and international markets was partly offset by softness in bone graft substitutes, or B…

DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine mont…

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for th…

On October 12, 2026, Bioventus Inc (BVS) shares rose 3.6% today, currently priced at $13.53. This move comes amid a 52-week range of $6.46 to $15.89.GF Value⢅

Bioventus (NASDAQ: BVS - Get Free Report) and Kestra Medical Technologies (NASDAQ: KMTS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies base…

RxSight (NASDAQ: RXST - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength…

Bioventus leverages cash from established products to reduce debt and fund commercial expansion, supporting a bullish outlook. BVS benefits from improved financing flexibility, with a term loan maturity extended to 2030 …

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.…

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

